On Monday, PTC Therapeutics earned an upgrade to its Relative Strength (RS) Rating, from 75 to 90.
IBD's unique RS Rating tracks technical performance by using a 1 (worst) to 99 (best) score that indicates how a stock's price action over the last 52 weeks matches up against the rest of the market.
Decades of market research reveals that the market's biggest winners often have an 80 or higher RS Rating as they begin their biggest price moves.
Looking For The Best Stocks To Buy And Watch? Start Here
PTC Therapeutics is now considered extended and out of buy range after clearing a 32.91 buy point in a first-stage cup without handle. See if the stock forms a new pattern or follow-on buying opportunity like a three-weeks tight or pullback to the 50-day or 10-week line.
The company reported 0% EPS growth in its most recent report. Revenue increased -5%.
PTC Therapeutics holds the No. 111 rank among its peers in the Medical-Biomed/Biotech industry group. ADMA Biologics, Halozyme Therapeutics and Sarepta Therapeutics are among the top 5 highly rated stocks within the group.
RELATED:
Biotech And Pharmaceutical Industry And Stock News
IBD Stock Rating Upgrades: Rising Relative Strength
Why Should You Use IBD's Relative Strength Rating?
How Relative Strength Line Can Help You Judge A Stock
Ready To Grow Your Investing Skills? Join An IBD Meetup Group!
